You have disabled JavaScript. [?]
Please enable JavaScript to see this page as intended.
:: ARCALYST Resource Center (ARC) ::

 Print This Page

Contact Information

Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
www.regeneron.com

For medical information, patient information, or reimbursement assistance please contact:


  • Tel: 
  • 1-877-REGN-777
  •         
  • 1-877-734-6777

  • E-mail: 

Important Safety Considerations

ARCALYST® (rilonacept) is a prescription medicine called an interleukin-1 (IL-1) blocker. ARCALYST is used to treat adults and children 12 years and older with Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).

ARCALYST can affect your immune system. ARCALYST can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death have happened in patients taking ARCALYST. Taking ARCALYST can make you more likely to get infections, including life-threatening serious infections, or may make any infection that you have worse.

You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming back (chronic infection).

After starting ARCALYST, if you get an infection, any sign of an infection including a fever, cough, flu-like symptoms, or have any open sores on your body, call your healthcare provider right away. Treatment with ARCALYST should be stopped if you develop a serious infection.

You should not take medicines that block Tumor Necrosis Factor (TNF) or IL-1 while taking ARCALYST. Taking ARCALYST with any of these medicines may increase your risk of getting a serious infection.

Call your healthcare provider or seek emergency care right away if you get any of the following symptoms of an allergic reaction while taking ARCALYST:

  • Rash
  • Swollen face
  • Trouble breathing


Common side effects with ARCALYST include

  • Injection-site reaction. This includes pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site
  • Upper respiratory infection
  • Changes in your blood cholesterol and triglycerides (lipids). Your healthcare provider will check you for this


These are not all the possible side effects of ARCALYST. Tell your healthcare provider about any side effects that bother you or that do not go away. For more information ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

The impact of treatment with ARCALYST on active and/or chronic infections and the development of malignancies (cancer) is not known. However, treatment with immunosuppressants, including ARCALYST, may increase the risk of malignancies.

Before starting treatment with ARCALYST, tell your healthcare provider if you

  • Think you have an infection
  • Are being treated for an infection
  • Have signs of an infection, such as fever, cough, or flu-like symptoms
  • Have any open sores on your body
  • Have a history of infections that keep coming back
  • Have asthma. Patients with asthma may have an increased risk of infection
  • Have diabetes or an immune system problem. People with these conditions have a higher chance for infections
  • Have tuberculosis (TB), or if you have been in close contact with someone who has had tuberculosis
  • Have or have had HIV, Hepatitis B, or Hepatitis C
  • Take other medicines that affect your immune system


Before you begin treatment with ARCALYST, talk with your healthcare provider about your vaccination history. Ask your healthcare provider whether you should receive any vaccinations, including pneumonia vaccine and flu vaccine, before you begin treatment with ARCALYST.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


The product information in this site is intended only for residents of the United States.
The products discussed herein may have different product labeling in different countries.